{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:52:42Z","timestamp":1769550762694,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s10067-022-06471-x","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T15:03:55Z","timestamp":1670943835000},"page":"959-962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["JAK inhibitors, cardiovascular and thromboembolic events: what we know and what we would like to know"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3822-3093","authenticated-orcid":false,"given":"Gerasimos","family":"Evangelatos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"6471_CR1","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","volume":"58","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, McInnes IB, Siebert S (2019) JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford) 58:i43\u2013i54. https:\/\/doi.org\/10.1093\/rheumatology\/key276","journal-title":"Rheumatology (Oxford)"},{"key":"6471_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA, Investigators OS (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386:316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"6471_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259","author":"C Charles-Schoeman","year":"2022","unstructured":"Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z (2022) Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2022-222259","journal-title":"Ann Rheum Dis"},{"key":"6471_CR4","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","volume":"81","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ (2022) Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis 81:798\u2013804. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221915","journal-title":"Ann Rheum Dis"},{"key":"6471_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222824","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E (2022) Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2022-222824","journal-title":"Ann Rheum Dis"},{"key":"6471_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","volume":"3","author":"JM Kremer","year":"2021","unstructured":"Kremer JM, Bingham CO 3rd, Cappelli LC, Greenberg JD, Madsen AM, Geier J, Rivas JL, Onofrei AM, Barr CJ, Pappas DA, Litman HJ, Dandreo KJ, Shapiro AB, Connell CA, Kavanaugh A (2021) Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol 3:173\u2013184. https:\/\/doi.org\/10.1002\/acr2.11232","journal-title":"ACR Open Rheumatol"},{"key":"6471_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223050","author":"V Molander","year":"2022","unstructured":"Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J, The ARTIS study group (2022) Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2022-223050","journal-title":"Ann Rheum Dis"},{"key":"6471_CR8","doi-asserted-by":"publisher","unstructured":"Salinas CA, Louder A, Polinski J, Zhang TC, Bower H, Phillips S, Song Y, Rashidi E, Bosan R, Chang HC, Foster N, Gershenson B, Yamanaka H, Kishimoto M, Tanaka Y, Fischer P, Zhu B, Faries D, Mai X, Doherty BT, Grelaud A, Thurin NH, Askling J, Deberdt W, Consortium BS (2022) Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther 1\u201323. https:\/\/doi.org\/10.1007\/s40744-022-00505-1","DOI":"10.1007\/s40744-022-00505-1"},{"key":"6471_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","volume":"61","author":"RJ Desai","year":"2021","unstructured":"Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC (2021) Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford) 61:121\u2013130. https:\/\/doi.org\/10.1093\/rheumatology\/keab294","journal-title":"Rheumatology (Oxford)"},{"key":"6471_CR10","unstructured":"Agency EM (2022) Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24\u201327 October 2022. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-24-27-october-2022#:~:text=EMA's%20safety%20committee%20(PRAC)%20has,clots%2C%20cancer%20and%20serious%20infections. Accessed 31\/10\/2022"},{"key":"6471_CR11","unstructured":"FDA (2021) FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death? Accessed 31\/10\/2022"},{"key":"6471_CR12","doi-asserted-by":"publisher","first-page":"1759720X2097697","DOI":"10.1177\/1759720X20976975","volume":"12","author":"GE Fragoulis","year":"2020","unstructured":"Fragoulis GE, Evangelatos G, Tentolouris N, Fragkiadaki K, Panopoulos S, Konstantonis G, Iliopoulos A, Chatzidionysiou K, Sfikakis PP, Tektonidou MG (2020) Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. Ther Adv Musculoskelet Dis 12:1759720X20976975. https:\/\/doi.org\/10.1177\/1759720X20976975","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"6471_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13075-017-1315-z","volume":"19","author":"K Bengtsson","year":"2017","unstructured":"Bengtsson K, Forsblad-d\u2019Elia H, Lie E, Klingberg E, Dehlin M, Exarchou S, Lindstrom U, Askling J, Jacobsson LTH (2017) Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther 19:102. https:\/\/doi.org\/10.1186\/s13075-017-1315-z","journal-title":"Arthritis Res Ther"},{"key":"6471_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13075-021-02703-8","volume":"24","author":"T Gazitt","year":"2022","unstructured":"Gazitt T, Pesachov J, Lavi I, Elias M, Haddad A, Feldhamer I, Cohen AD, Saliba W, Zisman D (2022) The association between psoriatic arthritis and venous thromboembolism: a population-based cohort study. Arthritis Res Ther 24:16. https:\/\/doi.org\/10.1186\/s13075-021-02703-8","journal-title":"Arthritis Res Ther"},{"key":"6471_CR15","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/acr.22039","volume":"65","author":"SC Kim","year":"2013","unstructured":"Kim SC, Schneeweiss S, Liu J, Solomon DH (2013) Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 65:1600\u20131607. https:\/\/doi.org\/10.1002\/acr.22039","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6471_CR16","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1136\/annrheumdis-2019-215854","volume":"80","author":"SW Lai","year":"2021","unstructured":"Lai SW (2021) Association between ankylosing spondylitis and venous thromboembolism. Ann Rheum Dis 80:e136. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215854","journal-title":"Ann Rheum Dis"},{"key":"6471_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","volume":"80","author":"V Molander","year":"2021","unstructured":"Molander V, Bower H, Frisell T, Askling J (2021) Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis 80:169\u2013175. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218419","journal-title":"Ann Rheum Dis"},{"key":"6471_CR18","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1093\/eurheartj\/ehx145","volume":"39","author":"A Ogdie","year":"2018","unstructured":"Ogdie A, Kay McGill N, Shin DB, Takeshita J, Jon Love T, Noe MH, Chiesa Fuxench ZC, Choi HK, Mehta NN, Gelfand JM (2018) Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J 39:3608\u20133614. https:\/\/doi.org\/10.1093\/eurheartj\/ehx145","journal-title":"Eur Heart J"},{"key":"6471_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Sodergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis 76:17\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209775","journal-title":"Ann Rheum Dis"},{"key":"6471_CR20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","volume":"81","author":"GC Drosos","year":"2022","unstructured":"Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, Boumpas DT, Brodin N, Bruce IN, Gonzalez-Gay MA, Jacobsen S, Kerekes G, Marchiori F, Mukhtyar C, Ramos-Casals M, Sattar N, Schreiber K, Sciascia S, Svenungsson E, Szekanecz Z, Tausche AK, Tyndall A, van Halm V, Voskuyl A, Macfarlane GJ, Ward MM, Nurmohamed MT, Tektonidou MG (2022) EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 81:768\u2013779. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221733","journal-title":"Ann Rheum Dis"},{"key":"6471_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223315","author":"N Conrad","year":"2022","unstructured":"Conrad N, McInnes IB, McMurray JJV, Sattar N (2022) Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)\u2019s recommendations for cardiovascular risk management? Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2022-223315","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06471-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06471-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06471-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T09:08:45Z","timestamp":1676538525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06471-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["6471"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06471-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GE has no conflicts of interest to declare. GEF has received honoraria\/speaker fees from AbbVie, Aenorasis, UCB, Novartis, Lilly, Pfizer, and Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}